Health-related quality of life among people who inject drugs in Australia

Cheng, Qinglu; Bajis, Sahar; Cunningham, Evan B; Shih, Sophy; Schulz, Marcel; Marshall, Alison D.; Martin, Natasha K.; Miners, Alec; Hajarizadeh, Behzad; Wiseman, Virginia; Dore, Gregory J.; Grebely, Jason

doi:10.1007/s11136-023-03465-3

Cited by 4 publications

(1 citation statement)

References 39 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This approach can enhance the overall quality of healthcare. Although several studies have examined HRQoL patterns among medical staff [ 19 ] and breast cancer patients [ 20 ], there is limited research on HRQoL among PWID [ 21 ]. Latent profile analysis (LPA) is a person-centered approach that can identify patterns or hidden subgroups based on individual responses from continuous data.…”

Section: Introductionmentioning

confidence: 99%

Patterns of Health-related Quality of Life in Men Who Inject Drugs: A Survey in Southeast Iran

Nojomi,

Rezapour,

Azar

et al. 2024

JPMPH

View full text Add to dashboard Cite

Objectives: Understanding patterns of quality of life in people who inject drugs (PWID) can help healthcare providers plan and manage their health problems in a more focused manner. Therefore, the current study aimed to identify patterns of health-related quality of life in PWID in southeast Iran.Methods: This cross-sectional study was conducted in southeast Iran on men who had injected drugs at least once during the last year. We used convenience sampling in 2 drop-in centers and venue-based sampling at 85 venues. Demographic characteristics, high-risk behaviors, and health-related quality of life were evaluated using the 5-level EQ-5D version (EQ-5D-5L) questionnaire. Latent profile analysis was used to identify patterns of quality of life.Results: This study enrolled 398 PWID, who had a mean age of 34.1±11.4 years. About 47.9% reported a prison history in the last 10 years, 59.2% had injected drugs in the last month, and 31.6% had a history of sharing syringes. About 46.3% reported having 2 or more sexual partners in the last 6 months, and 14.7% had a history of sex with men. Out of the 5 EQ-5D-5L profiles, the fifth profile had the most people (36.6%). Most variations in quality of life were related to pain and discomfort.Conclusions: We showed that the pain and discomfort dimension of EQ-5D-5L had more variation in PWID. This finding will be useful for allocating appropriate interventions and resources to promote health-related quality of life in this population.

show abstract

Section: Introductionmentioning

confidence: 99%

Patterns of Health-related Quality of Life in Men Who Inject Drugs: A Survey in Southeast Iran

Nojomi,

Rezapour,

Azar

et al. 2024

JPMPH

View full text Add to dashboard Cite

show abstract

Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study

Cheng,

Valerio,

Cunningham

et al. 2024

Value in Health

View full text Add to dashboard Cite

Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination

Shih,

Stone,

Martin

et al. 2023

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background The Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study demonstrated that scaling-up of direct-acting antiviral (DAA) treatment reduced hepatitis C virus (HCV) transmission. We evaluated the cost-effectiveness of scaling-up HCV treatment in state-wide prison services incorporating long-term outcomes across custodial and community settings. Methods A dynamic model of incarceration and HCV transmission amongst people who inject drugs (PWID) in New South Wales, Australia, was extended to include former PWID and long-term HCV progression. Using Australian costing data, we estimated the cost-effectiveness of scaling-up HCV treatment in prisons by 44% (as achieved by the SToP-C study) for 10 years (2021-2030) before reducing to baseline levels, compared to a status-quo scenario. The mean incremental cost-effectiveness ratio (ICER) was estimated by comparing the differences in costs and quality-adjusted life-years (QALYs) between the scale-up and status-quo scenarios over 40 years (2021 to 2060) discounted at 5% per annum. Univariate and probabilistic sensitivity analyses were performed. Results Scaling-up HCV treatment in the state-wide prison service is projected to be cost-effective with a mean ICER of A$12,968/QALY gained. The base-case scenario gains 275 QALYs over 40 years at a net incremental cost A$3.6 million. Excluding DAA pharmaceutical costs, the mean ICER is reduced to A$6,054/QALY. At the willingness-to-pay threshold of A$50,000/QALY, 100% of simulations are cost-effective at various discount rates, time horizons, and changes of treatment levels in prison and community. Conclusion Scaling-up HCV testing and treatment in prisons is highly cost-effective and should be considered a priority in the national elimination strategy.

show abstract

Health-related quality of life among people who inject drugs in Australia

Cited by 4 publications

References 39 publications

Patterns of Health-related Quality of Life in Men Who Inject Drugs: A Survey in Southeast Iran

Patterns of Health-related Quality of Life in Men Who Inject Drugs: A Survey in Southeast Iran

Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study

Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination

Contact Info

Product

Resources

About